Ambry Genetics Announces 508 FIRST Cystic Fibrosis Test $59 Assay Detects the Most Common Cystic Fibrosis Mutation

FOR IMMEDIATE RELEASE

Ambry Genetics
15 Argonaut
Aliso Viejo, CA 92656

Samples from patients that prove negative for DeltaF508 will be automatically routed to the Ambry Test: CF AMPLIFIED™ for the most comprehensive analysis available. With a detection rate of approximately 99%, no other test can identify more mutations than the Ambry Test: CF AMPLIFIED™.

Ambry Genetics President & CEO, Charles L. M. Dunlop, explains: "508 FIRST™ is the optimum start point for complete gene analysis of any Cystic Fibrosis patient. 508 FIRST™ provides a quick and affordable screen for the most likely positive result, with the security and confidence of full gene analysis in a single test."

"The certainty that comes with precise genetic results can reduce the cost of further tests, and help doctors provide the most effective care," Mr. Dunlop said. Because Ambry Genetics treats both phases of 508 FIRST™ as a single test, the process of arriving at definitive diagnosis of CF is covered more easily by insurance.


About Ambry Genetics ®

Ambry Genetics is both College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified. Ambry leads in clinical genetic diagnostics and genetics software solutions, combining both to offer the most comprehensive testing menu in the industry. Ambry has established a reputation for sharing data while safeguarding patient privacy, unparalleled service, and responsibly applying new technologies to the clinical molecular diagnostics market. For more information about Ambry Genetics, visit ambrygen.com.

Press Contact:
Aaron Schmidt
Sr Manager, Communications
aschmidt@ambrygen.com
949 457 4679

Search Results

Start your search...